Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 1

Conditions

Mesothelioma, Malignant 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × amatuximab × Clear all
NCT00738582 2022-09-22

Amatuximab

Morphotek

Phase 2 Completed
89 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT00570713 2015-09-09

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Morphotek

Phase 2 Completed
155 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡